INTRODUCTION
Lymphomas are complex, potentially life limiting haematological (blood) malignancies that have a marked impact on quality of life and long-term health as a consequence of the aggressive or chronic nature of the treatments required to manage them (Carey et al., 2012) . Lymphomas are immune-related cancers, broadly categorised as non-Hodgkin or Hodgkin lymphoma, and can be indolent or aggressive in nature (National Cancer Institute, 2016) . Advances in treatment efficacy, including haematopoietic stem cell transplants, bone marrow support with blood component transfusions and white cell stimulation, along with advances in decreasing severity of infection risk, remission rates have improved (Lichtman, 2008) .
In Australia, the context for this study, the 2012 estimated age-standardised rates (ASRs) of Hodgkin lymphoma incidence and mortality were 2.7 and 0.3 respectively (Cancer Australia, 2017a) . These figures compare favourably with the European Union (EU-27) estimated ASRs of Hodgkin lymphoma incidence (2.3) and mortality (0.4) for the same period (Ferlay et al., 2013) . The estimated Australian ASRs of incidence and mortality for Non-Hodgkin lymphoma were 19.1 and 5.4 respectively compared with EU-27 estimated ASRs of 11.6 and 3.8 respectively (Cancer Australia, 2017b; Ferlay et al., 2013) Late and long-term side effects of treatment for lymphoma are common and can include fatigue; nutritional and physical activity deficits; fertility, sexuality and relationship concerns; and financial, employment and insurance issues (Allart et al., 2013; Arden-Close et al., 2011; Hall et al., 2013b) . As advances in remission and cure rates improve, survivors are living longer with the consequences of their disease and treatment (Sant et al., 2014) , and many experience unmet needs that impact long-term health and wellbeing (Arden-Close et al., 2011) . In a study of 53 long-term survivors of leukaemia and lymphoma (Zebrack, 2000) , issues such as fatigue (n=23, 42%), remained an ongoing problem. The authors indicated fear of recurrence and financial concerns were also predominant factors in long-term survivors (no figures given). In a study of 437 haematology survivors in Australia and Canada, fatigue was identified as the greatest unmet concern (n=76, 16%), with the Australian cohort only (n=268, 61%) reporting a higher level of unmet financial concerns (n=39, 15%) (Hall et al., 2013a) .
Survivors of haematological malignancies have been show to experience ongoing issues up to a decade or more post-treatment completion (Ferrer et al., 2011) . Severe fatigue impacting functional capacity, emotional well-being and ability to return to work (Ferrer et al., 2011; Kangas et al., 2008; Oerlemans et al., 2013) , and persistent cognitive impairment have been reported as debilitating long-term effects of treatment (van der Poel et al., 2014) .
There is limited evidence available to inform the development of patient-focused haematology survivorship services in Australia. However, some evidence exists to indicate patients' preferences for post-treatment follow-up care. In a study of 66 cancer survivors representing the major haematological diagnostic groups (non-Hodgkin lymphoma 48%, Hodgkin lymphoma 12%, multiple myeloma 26%, leukaemia 14%), help with managing the fear of recurrence (42%) and ongoing case management (33%) were identified as unmet needs in the post-treatment period (Lobb et al., 2009) . The opportunity to discuss experiences with a health care professional at treatment completion was identified as potentially helpful by 59% of participants. McGrath (2014) reported findings from a qualitative study of 50 haematology survivors that explored use of routine telephone follow-up as a supportive care strategy. The sample represented the haematologic diagnostic groups of multiple myeloma (n=15), lymphoma (n=14) and leukaemia (n=17). Although telephone follow-up support was perceived by the majority of participants as potentially beneficial, many individuals did not support the idea as they wanted to 'move on' from cancer and would not have welcomed any contact.
Unlike more common malignancies such as breast and prostate cancer, evidence to inform the development of optimal follow-up guidelines for haematological survivorship care is lacking. This study set out to explore the experiences of and preferences for post-treatment support in Australian survivors of lymphoma 6-30 months post-treatment completion. For the purpose of the study, participants were deemed 'lymphoma survivors' if their haematologist had documented ongoing remission at least six months from treatment completion as our intent was to better understand posttreatment support needs.
METHODS

Methodological Framework
We undertook a qualitative, descriptive study (Neergaard et al., 2009; Sandelowski, 2000) utilising focus groups to explore and better understand the posttreatment experiences and support needs of lymphoma survivors. Focus groups allow for collection of a broad range of information and insight when little is known or understood about a topic (Neergaard et al., 2009; Sandelowski, 2000) , while providing peer support and normalisation of experiences that group participants may share.
Excellent facilitation is important to ensure all participants have an opportunity to contribute as they wish, avoiding dominance of one or two experiences (Tausch and Menold, 2016) . For the purpose of our study, a PhD prepared haematology clinical psychologist experienced in conducting focus groups with vulnerable populations, facilitated the digitally recorded focus groups and was supported by a specialist cancer nurse who acted as scribe to support detail and accuracy of interpretation of the digitally recorded focus group data.
The study was approved and undertaken in accordance with the ethical standards guiding the Human Research Ethics Committees of the relevant study site and university. Informed written consent was obtained from all participants prior to study participation.
Sample and setting
The study was undertaken at a large tertiary hospital with a comprehensive cancer centre in Western Australia. Between 1 July 2009 and 1 December 2013, 479 patients were referred to the hospital for treatment of lymphoma. Potentially eligible study participants were identified through a manual search of the hospital cancer registry patient records. Eligibility criteria included: i) aged over 25 years (in Australia Youth Cancer Services provide specialist, age-appropriate treatment and support for young cancer patients aged 15 -25; ii)) currently residing in Western Australia; iii) fluent in English; iv) completed treatment at least 6 months prior to study; and v) no cognitive impairment (as indicated in the medical record or during recruitment process where participants' ability to understand the study details and provide consent was assessed).
Exclusion criteria were patients who: i) had relapsed after first-line therapy; ii) were receiving care or follow-up or had undertaken an allogeneic transplant at another hospital; and iii) were undergoing work-up for autologous transplant. These exclusion criteria ensured experiences from other hospital sites and continuing treatment experiences did not influence the data collected.
Focus Groups
Two digitally recorded focus groups were carried out and data from each group transcribed verbatim. The transcriptions were checked for accuracy by the facilitator and support nurse, drawing on the notes taken during the groups and by listening to the recordings. Digital recordings of interviews and transcribed interviews were saved in password-protected files on a secure server. 
Data Analysis
The focus group transcript data were imported into NVivo to enable the management of data, and the process of data analysis. Thematic content analysis methodology was applied to explore and organise data into codes and themes (Braun and Clarke, 2006) . Transcripts were initially coded by CB. Subsequently each transcript was read independently by two other members of the study team (TM, KT). Thematic content analysis is a widely used analytical approach to qualitative data where themes, identified through coding, reflect key patterns within the textual data. This inductive approach was regarded as the most appropriate for our data, allowing themes to emerge from the content of the focus groups rather than considering data in response to questions pre-constructed by the researchers (Sarantakos, 2013). Data saturation point was reached following analysis of the two focus groups.
Rigour
Researchers (KT, CB and TM) met to discuss outcomes from the independent coding process and agreed on emerging themes. Discrepancies were discussed until consensus was reached. This allowed for development of a coding system that ensured a strategy of reliability throughout the process (Morse, 2015) . Rigour of data analysis was ensured by applying the criteria of credibility, auditability and fittingness (Beck, 1993) . Credibility was obtained through use of researchers to complete independent coding thereby ensuring categories accurately captured issues being discussed.
Decisions related to allocation of discrete data elements to codes and fittingness of the codes, were demonstrated through extensive use of quotes or extracts from the data. Documentation of all steps in the analysis process, including opportunities for reflection on the codes and debriefing about the content of the transcription ensured a coherent audit trail and therefore maintained auditability.
RESULTS
Participants
Of the 79 eligible lymphoma participants, 11 returned opt-out forms without providing a reason for this decision. The remaining 68 participants were contacted to further explain the study and provide focus group details. Of these 22 (32%) agreed to participate in a focus group, however five people did not attend on the day. Reasons for non-participation included: migrating overseas / interstate (n=2); recently relapsed or other cancer (n=5); family bereavement (n=1); working fulltime (n=1); declined to provide a reason when contacted by telephone (n=20); did not respond to voicemail message (n=13); severe symptom burden (n=1); unable to arrange transport (n=1); family objection (n=1); deceased (n=1).
The disease and demographic characteristics of the participants who did not take part in a focus group were comparable with those who participated. The age range of participants was 27 to 85 years with a mean age of 63.8 years (SD 14.5). The average time since last treatment was 14.6 months (SD 8.2) with a range of 6-30 months (Table   1) . Many participants spoke about coping with the emotional experience and impact of their cancer treatment through avoidance:
"I can personally say that I did have my down moments … but it's so hard and I thought it's worse being in this state, just get out-just get going, just don't think about it -it's easier to just get on with it rather than get depressed -I know that's easier said than done."
F_28yo_NHL
Living with the fear of cancer recurrence was described as a common experience and although one or two participants talked about seeking help and reassurance to address their fear, most described getting on with living alongside the uncertainty and fear:
"I don't think you ever quite get rid of the shadow … I don't think you ever get free of that slightly depressed feeling that's in the back of your head that it could come back." The most commonly mentioned strategies used post-treatment to try and cope with the impact of their diagnosis, its treatment and on-going uncertainty included exercise, having children around, and hope for the future: 
F_46yo_NHL "I think having kids around brings you up a bit and makes you realise that life isn't so tough…" F_28yo_NHL "…but also you need to be busy mentally and do things for the future and I really amazed myself in two months after chemo when I planted my vegetables and I thought 'will I be alive to eat it'." F_46yo_NHL
Family and significant others, support and post-treatment experience Family members and significant others were largely seen as helpful but at times participants described experiences where they could be unintentionally dismissive and appeared to lack understanding: Some participants commented that as they physically and outwardly began to look better, others' expectations of them changed:
"But when your hair grows again and your skin colour comes back and you're not passed out in the chair most of the time, … people tend to quickly move on from that where as you haven't you know what I mean, you haven't'. … whilst you're not having chemo any more it's not finished for you yet…" M_48yo_HL
Some participants had found value in attending peer support groups where others understood what they had gone through and experienced:
"It's just like everybody's been saying, it's nice to come where people understand you -I mean that my family and friends have all been amazing but they don't understand. They just all say yes we know you're going through it and we feel for you, but they just don't understand." F_46yo_NHL
One participant found the support received from belonging to a group of other young people made a big difference to their experience:
"… I couldn't kind of get along with the people I was having treatment with just because our lives were so different. It was so helpful … I just went to those little meetings and there were people my age talking about the same sort of stuff." F_28yo_NHL
But for others a group situation was difficult, at times overwhelming, leaving them feeling uncomfortable:
"You're always identified as the cancer person or with the cancer group … but sometimes it weighs a bit heavy, like the people there you don't necessarily want to broadcast it to the whole world." F_75yo_NHL
Transition, connectivity and normalcy
The relationships established during treatment and the security that came through knowing they were being treated and monitored closely by an expert or team who genuinely cared for them was greatly valued: 
F_28yo_NHL
But moving from the structure of treatment and hospital support back into "normal life" was difficult. Some expected to return to their life as it was pre-diagnosis and found it challenging when this did not happen:
"… when your chemo's finished they kept telling me it would take a year to get back to normal and I'm like 'you don't know me, that's not going to happen, I'm going to walk out of here and flip a switch and I'm going to be back to normal' well it's not the case."
M_51yo_NHL
The need to find a new meaning or purpose post-treatment and a realisation that one had changed and that what matters in life had changed were strong elements in the data gathered: Moving away from the "cancer label" and not wanting to be stigmatised was important for many participants as they transitioned into the post-treatment phase: However, most participants felt that some sort of "check-up" (follow-up) appointment at the hospital around one month post-treatment would be helpful where the focus was on the experience of the individual rather than the disease: Peer support was also described as valuable when the peer had undergone a similar experience and for some people it was important to get away from "the medics": Information needs varied across participants in our study, reflecting findings from other qualitative studies of haematological cancer survivors (Gansler et al., 2010) and emphasising the importance of flexibility in services developed if they are to successfully address the information needs of post-treatment survivors. Participants in this study described difficulty in accessing the kind of information they needed from tertiary and community health professionals once the acute treatment period was over, a finding commonly reported in studies of non-haematology cancer survivors (Taylor and Monterosso, 2016) . Participants described a sense of loss in terms of support, connectivity and reassurance when they transitioned away from active care to the posttreatment phase, indicating that there is opportunity to develop and implement tailored post-treatment preparation interventions to enhance the experience and wellbeing of haematology survivors. Living with fear of cancer recurrence was a common experience for participants in our study, and is widely recognised as one of the most distressing or prevalent concerns of cancer survivors (Butow et al., 2015; Park et al., 2013) . Helping people find strategies to live with fear of recurrence is a key issue in the advancement of post-treatment survivorship care.
Dealing with the side effects of treatment was described as one of the most difficult aspects of the post-treatment phase. Participants in our study felt they weren't adequately prepared to manage the issues they faced, and suggested that information on the duration of side effects, what to expect and how to cope with them would have been helpful. This finding offers an important and achievable target for improvement in post-treatment care of survivors of lymphoma.
Some participants described difficulty in adjusting to a "new normal" posttreatment and actively sought a new sense of purpose and identity. A clear sense of moving away from cancer and putting it to one side so that a new norm could be established was evident for some. This finding suggests that working with patients ahead of treatment completion to prepare a "new narrative" for themselves may better support people to transition from their identity as a cancer patient.
Although there was a general recognition of the value of support provided through existing family and friend networks, some participants felt that once they started to look and feel better, family or significant others' expectations of what they were capable of doing exceeded what they felt ready or able to do. The need to develop survivorship services that directly support families or important others so they can be effective partners in the transition to life post-treatment, as well as keep themselves well, is evident.
In response to questions about helpful components of post-treatment care, many participants described the ability to contact a health professional to seek reassurance, check in about concerning symptoms and get advice and information as an important element in enabling confident transition to survivorship. Specialist post-treatment nurse care coordinators working across tertiary and community settings may offer an effective model to address this need for survivors of haematological malignancies.
A follow-up appointment post-treatment focusing on refection of the diagnosis and treatment experience as a way of being able to "move on" to the next phase of life was also recommended as a potentially useful intervention and is worthy of consideration as one component of person-centred post-treatment care.
Limitations
The limitations in this study include the small sample size and the single site recruitment. However, the findings do offer valuable insight into the post-treatment experiences and support needs of participants in our study, and offer tangible opportunity for the development of post-treatment services and interventions targeted to the needs of survivors of lymphoma, although more works needs to be done to establish the credibility of our findings to other haematological cancer patients' post-treatment.
Participants chose to opt-in and therefore it is not possible to assess whether those with greater needs or worse experiences of post-treatment care excluded themselves.
However, experiences of those people who gave their time to take part have provided a valuable addition to a small but growing body of research in this area. The use of a clinical psychologist as the facilitator for the focus groups (disclosed to participants at the beginning of the focus group) may have influenced the issues participants chose to share or withhold dependent on previous access to or attitudes toward a psychologist.
CONCLUSION
Survivors of lymphoma experience many and complex post-treatment issues that require tailored intervention as part of a comprehensive package of person-centred post-treatment care. Data from our study suggest that integration of professional, peer and family/important other support strategies may prove to be most effective. Specialist haematology nurse care coordinators working across tertiary and community settings could offer a feasible and efficient way of coordinating tailored programs of support around survivors of haematological malignancies.
